NAC (N-Acetylcysteine)
SupplementThe small divergence (4 points) reflects good agreement between clinical evidence [s4, s7] and community experience [c1, c2]. The community rates NAC somewhat more conservatively than comparable antioxidants, reflecting brand-dependent quality variability [c3] and uncertain psychiatric effects [s7].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
NAC is one of the best-supported supplements available: it measurably reduces COPD exacerbations (RR 0.76 across 10 RCTs), is the clinical standard for paracetamol overdose, and multiple RCTs show significant improvements in sperm parameters for male infertility. Oral bioavailability is a sobering 6–10%, so dosing needs to account for that. Psychiatric indications like OCD show trends but no statistically robust effects yet. In Germany, NAC sits in a legal grey zone as a supplement — as a pharmaceutical it requires a prescription.
Description
NAC is an amino acid precursor of glutathione with antioxidant, mucolytic, and hepatoprotective properties; clinically established in paracetamol overdose and COPD [s1, s2, s3].
N-Acetyl-Cysteine (NAC) is an acetylated derivative of the semi-essential amino acid L-cysteine. In the body, NAC is converted by deacetylation to cysteine, the rate-limiting substrate for the synthesis of glutathione (GSH) – the most important endogenous antioxidant [s1, s2]. NAC has several clinically relevant activity profiles: 1. **Mucolytic in respiratory diseases**: NAC cleaves disulfide bonds in mucus, reduces sputum viscosity, and has been used in chronic bronchitis and COPD for decades [s3, s4]. A meta-analysis showed that low-dose NAC significantly reduces the risk of COPD exacerbations (RR 0.76; 95% CI 0.65–0.89) [s4]. 2. **Antidote in paracetamol overdose**: NAC is the standard treatment for acute paracetamol intoxication. When administered within 8 hours of overdose, the risk of hepatotoxicity decreases to approximately 5% [s5]. Both intravenous and oral administration are effective [s6]. 3. **Psychiatric disorders**: Several RCTs have investigated NAC as adjunctive therapy in obsessive-compulsive disorder (OCD). A 2024 meta-analysis identified a trend toward greater efficacy at higher doses, without statistical significance over 12 weeks [s7]. Systematic reviews show limited but present evidence for OCD, bipolar disorder, and schizophrenia [s8]. 4. **Male fertility**: Several RCTs and a meta-analysis demonstrate significant improvements in sperm parameters (concentration, motility, morphology, volume) in idiopathic male infertility [s9, s10]. 5. **Neuroprotection**: NAC is being investigated as a potential neuroprotective agent in Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions; however, clinical evidence remains limited [s11, s12]. The oral bioavailability of NAC is relatively low at 6–10% [s13]. Doses of 600–2400 mg/day are commonly used clinically.
Legal Status (DE)
In Germany, acetylcysteine (NAC) as a pharmaceutical active substance is subject to prescription requirements under § 48 AMG when placed on the market as a medicinal product [s14]. As a dietary supplement, NAC is legally controversial in Germany: the BfR does not clearly classify it as a marketable dietary supplement [s14]. There is no harmonized authorization as a dietary supplement ingredient in the EU. In the United States, the FDA has determined that NAC is formally excluded from the definition of a dietary supplement, but exercises enforcement discretion as long as no safety risk exists [s15, s16]. Products marketing NAC as a dietary supplement therefore operate in a legal grey area.
Mechanism of Action
NAC acts through several complementary mechanisms [s1, s2]: 1. **Glutathione synthesis (primary mechanism)**: Following oral absorption, NAC is predominantly deacetylated in the liver, releasing cysteine, which enters GSH synthesis as the rate-limiting substrate. GSH is a central intracellular antioxidant that neutralizes reactive oxygen species (ROS) [s1, s2]. 2. **Direct radical-scavenging activity**: NAC can directly scavenge free radicals without prior conversion to glutathione, via the free thiol group (-SH) of the molecule [s2]. 3. **Mucolytic activity**: NAC cleaves disulfide bonds (-S-S-) between mucoproteins in bronchial mucus, reducing secretion viscosity and facilitating expectoration [s3, s4]. 4. **H₂S and sulfane sulfur formation**: Recent research shows that NAC can be converted in biological systems to hydrogen sulfide (H₂S) and polysulfides. These compounds possess independent antioxidant and cytoprotective properties that may contribute to many effects previously attributed to NAC or GSH [s17]. 5. **Modulation of glutamate and oxidative stress in the CNS**: In the brain, NAC influences glutamate levels via the cystine-glutamate exchanger (xCT). This mechanism is discussed as a possible basis for the psychiatric effects (OCD, bipolar disorder, schizophrenia) [s7, s8]. 6. **Anti-inflammatory effects**: Through GSH upregulation and direct thiol chemistry, NAC modulates pro-inflammatory signaling pathways (NF-κB) [s2].
Dosing
Mukolytikum / Atemwegsgesundheit (COPD, Bronchitis)
- Dose
- 600 mg
- Frequency
- 1–3× täglich
- Route
- oral
- Duration
- fortlaufend oder saisonal
- Timing
- With meals
- With food
- empfohlen
Paracetamol-Überdosierung (klinisch, stationär)
- Dose
- Intravenous: 150 mg/kg over 15–60 min, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h (Rumack protocol)
- Frequency
- Einmalige mehrstufige Infusion
- Route
- oral
- Duration
- ca. 21 Stunden
- Timing
- As early as possible, ideally within 8 hours of ingestion
- With food
- optional
Antioxidans / allgemeine Gesundheit
- Dose
- 600–1200 mg
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- fortlaufend, zyklisch empfohlen
- Timing
- Fasted or with meals
- With food
- optional
OCD / Psychiatrische Zusatztherapie (nur unter ärztlicher Aufsicht)
- Dose
- 2000–3000 mg
- Frequency
- aufgeteilt auf 2 Dosen täglich
- Route
- oral
- Duration
- 12–16 Wochen
- Timing
- Morning and evening
- With food
- empfohlen
Männliche Fertilität
- Dose
- 600 mg
- Frequency
- 2× täglich
- Route
- oral
- Duration
- 3 Monate
- Timing
- With meals
- With food
- empfohlen
In a clinical study, 11.6 g/day orally over 3 months was observed without serious adverse effects [s18]. Nevertheless, doses above 2400 mg/day are not recommended without a medical indication and medical supervision. For intravenous administration in emergency settings, separate clinical protocols apply [s5, s6].
The oral bioavailability of NAC is only 6–10% and varies depending on the dosage form (rapidly dissolving tablet > slow-release) [s13]. Some users report brand-dependent quality differences [c3]. NAC can chelate zinc and copper; micronutrient status should be monitored with long-term high-dose use [c2].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Erbrechen, Durchfall, Bauchschmerzen) Most common adverse effect with oral administration. Generally mild and transient at therapeutic doses [s18, s19]. | gelegentlich | leicht |
| Schwefelähnlicher Atem- und Körpergeruch Caused by sulfur metabolites of cysteine and NAC; not clinically relevant but cosmetically bothersome [s18, s19]. | gelegentlich | leicht |
| Anaphylaktoide Reaktionen (Hautausschlag, Urtikaria, Juckreiz, Hypotension) Primarily with intravenous administration; anaphylactoid reactions observed in up to 18% of IV patients, mostly during the early infusion phase. Considerably less frequent with oral administration [s19, s20]. | selten | schwer |
| Kopfschmerzen Reported by individual users, partly brand-dependent [c3]. No clear clinical mechanism established. | selten | leicht |
| Zink- und Kupfer-Chelation (potenzieller Mikronährstoffmangel bei Hochdosierung) NAC can bind divalent metal ions such as zinc and copper. Theoretically relevant with long-term high-dose intake; clinical studies are lacking [c2]. | theoretisch | moderat |
| Bronchospasmus (bei inhalativer Anwendung) Paradoxical bronchospasm may occur with inhaled NAC (e.g., as inhalation solution), particularly in patients with bronchial asthma [s20]. | selten | moderat |
Contraindications
Anaphylactoid reactions are documented; NAC is contraindicated in cases of known hypersensitivity [s19, s20].
Inhaled NAC can trigger bronchospasm; oral administration is less risky in asthma, but caution is advised [s20].
Safety data during pregnancy are limited. NAC should only be used during pregnancy after careful benefit-risk assessment by a physician [s20].
Combination may cause pronounced hypotension and headache, as NAC potentiates the vasodilatory effect of nitrates [s20].
Interactions
Synergistic
NAC increases intracellular glutathione synthesis, while alpha-lipoic acid acts both as a direct antioxidant and regenerates depleted glutathione, resulting in mutual potentiation of their antioxidant effects.
BPC-157 promotes tissue repair and modulates the NO signaling pathway and angiogenesis, while NAC reduces oxidative stress via glutathione elevation; both mechanisms complement each other synergistically in cytoprotection and wound healing.
As a direct glutathione precursor, NAC increases intracellular glutathione synthesis, acting synergistically with exogenously administered glutathione. Studies indicate that the combination of NAC, vitamin D3, and glutathione has a cooperative effect on oxidative homeostasis.
Caution
At higher doses (from approx. 1200 mg), NAC can chelate zinc and other essential minerals, thereby reducing their absorption. Zinc supplements should be taken at a staggered time (at least 2–3 hours after NAC).
NAC interacts with copper ions and can, under certain conditions, generate reactive oxygen species (H₂O₂). Simultaneously, NAC may act as a chelator affecting copper bioavailability, thereby altering the activity of copper-dependent enzymes (e.g., SOD1).
As a thiol chelator, NAC may impair the absorption of iron supplements when taken concurrently. A time interval of at least 2–3 hours is recommended to ensure optimal iron absorption.
Studies
Tier A — High Evidence
Outcome: Reduction of COPD/bronchitis exacerbations
Effect Size: RR 0.76 (95% CI 0.65–0.89; p<0.01) for low-dose NAC
Outcome: Reduction of Y-BOCS score in OCD (adjunctive therapy)
Effect Size: Trend toward greater efficacy at higher doses; no statistical significance over 12 weeks
Outcome: Improvement of sperm parameters in idiopathic male infertility
Effect Size: Significant improvement in sperm concentration, motility, morphology, and volume
Outcome: Sperm parameters and pregnancy outcomes
Effect Size: MD sperm volume +0.69 (p=0.002); MD concentration +4.43 (p=0.003); MD motility +9.69
Outcome: Reduction of hepatotoxicity in paracetamol overdose
Effect Size: Hepatotoxicity risk 5% with treatment within 8h vs. >50% without treatment
Tier B — Moderate Evidence
Outcome: NAC in neurological disorders (Parkinson's, Alzheimer's, MS, stroke)
Effect Size: Preliminary positive signals; clinical evidence still insufficient for recommendations
Outcome: NAC in non-paracetamol-induced acute liver failure
Effect Size: No clear survival benefit, but well-tolerated use confirmed
Outcome: NAC in psychiatric disorders (OCD, bipolar disorder, schizophrenia)
Effect Size: Limited but existing evidence for OCD and bipolar disorder; insufficient for anxiety and ADHD
Tier C — Low Evidence
Outcome: Novel mechanism of action via H₂S and polysulfides
Effect Size: Mechanistic evidence; no clinical endpoints
Outcome: NAC in neurodegenerative diseases: Parkinson's, Alzheimer's
Effect Size: Animal and in vitro data; clinical translation still pending
Community Evidence
Top reported benefits
- Relaxation and mental calm / 'zen feeling'
- Improved focus and concentration at work
- Positive effects on respiratory tract and mucous membranes
- Energy and general well-being
- Hepatoprotection / detox effects (especially post-alcohol)
- Possible support for OCD / rumination
Top reported issues
- Brand-dependent quality differences (headaches with cheap brands)
- Unpleasant sulfur odor
- Mild nausea when taken on an empty stomach
- Concerns about possible zinc/copper depletion with long-term use
Some users discuss whether long-term NAC use downregulates endogenous glutathione synthesis (hormetic effect); scientific consensus on this is lacking [c2]. The FDA regulatory situation in the US causes uncertainty among some users regarding availability [c1]. Interindividual responsiveness is high – a proportion of users report no perceptible effects [c3].
Scientific Sources
- N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why
Rushworth GF, Megson IL (2014). Free Radical Biology and MedicineBPMID:24080471DOI - Unlocking the potential of antioxidant supplementation with n-acetylcysteine to improve seminal parameters and analysis of its safety: a systematic review and meta-analysis of randomized controlled trials
Greco E, Rienzi L, Ubaldi FM, et al. (2025). AndrologyADOI - N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders
Corona JC, Duchen MR (2026). International Journal of Molecular SciencesADOI - Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases
Tardiolo G, Bramanti P, Mazzon E (2018). MoleculesBPMID:30551603DOI - Pharmacokinetics of N-acetylcysteine in man
Borgström L, Kågedal B, Paulsen O (1986). European Journal of Clinical PharmacologyBDOI - N-Acetyl-L-Cystein in kosmetischen Mitteln – Bewertung des BfR
Bundesinstitut für Risikobewertung (BfR) (2020). BfR-StellungnahmeALink - Guidance for Industry: Policy Regarding N-acetyl-L-cysteine
U.S. Food and Drug Administration (FDA) (2022). FDA Guidance DocumentsALink - Federal Register: Policy Regarding N-acetyl-L-cysteine; Guidance for Industry; Availability
U.S. Food and Drug Administration (FDA) (2022). Federal RegisterALink - The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species
Zafarullah M, Li WQ, Sylvester J, et al. (2021). Pharmacology & TherapeuticsBDOI - Acetylcystein – Wikipedia (Dosierung und Sicherheit)
Wikipedia-Autoren (2024). Wikipedia (DE)CLink - Acetylcystein: Wirkung, Einnahme, Risiken
netDoktor-Redaktion (2023). netDoktor.deCLink - N-Acetylcysteine Pharmacology and Applications in Rare Diseases—Repurposing an Old Antioxidant
Šalamon Š, Kramar B, Marolt TP, et al. (2023). Antioxidants (MDPI)BDOI - N-Acetylcysteine – StatPearls
Mokhtari V, Afsharian P, Shahhoseini M, et al. (2023). StatPearls – NCBI BookshelfBLink - The Antioxidant Role of Glutathione and N-Acetyl-Cysteine Supplements and Exercise-Induced Oxidative Stress
Kerksick C, Willoughby D (2005). Journal of the International Society of Sports NutritionBDOI - The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit
Teder K, Maddison L, Soeorg H, Meos A, Karjagin J (2021). MedicinaCPMID:34833436DOI - The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice
Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE (2003). Journal of NeurochemistryCPMID:12603840DOI - N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses
Cazzola M, Rogliani P, Calzetta L, et al. (2024). COPD: Journal of Chronic Obstructive Pulmonary DiseaseADOI - Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
Cazzola M, Calzetta L, Page C, et al. (2015). European Respiratory ReviewADOI - N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review
Yoon E, Babar A, Choudhary M, et al. (2022). Frontiers in PharmacologyBDOI - Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systematic review
Squires RH, Dhawan A, Alonso E, et al. (2021). Journal of HepatologyADOI - The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials
Ghanei A, Farsi F, Hosseini SA, et al. (2024). Frontiers in PsychiatryADOI - Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala D, Slattery J, Kumar N, et al. (2015). Neuroscience & Biobehavioral ReviewsAPMID:26037430DOI - The role of N-acetyl-cysteine (NAC) orally daily on the sperm parameters and serum hormones in idiopathic infertile men: A systematic review and meta-analysis of randomised controlled trials
Zhou X, Du L, Shi R, et al. (2021). AndrologiaADOI
Community Sources
Storage
Unopened
Store in a cool, dry place (15–25 °C), protected from direct sunlight.
Opened
Keep container tightly closed; avoid moisture. Powder forms should be used promptly after opening.
Notes
NAC is sensitive to oxidation; the powder may turn yellowish upon improper storage, indicating degradation. Effervescent tablets must be consumed immediately after dissolution.